Evidence map›Paper›PMID 37923835›Full record

ArticleNPJ precision oncology2023

In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy.

Sara Corvigno, Sunil Badal, Meredith L Spradlin, Michael Keating, Igor Pereira, Elaine Stur, Emine Bayraktar, Katherine I Foster, Nicholas W Bateman, Waleed Barakat and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. A Urinary Three-Metabolite Signature Enables Noninvasive Identification of Patients with High-Risk Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Laser capture microdissection.Nature reviews. Methods primers · 2025
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 1 country.

Sara CorvignoDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sunil Badal *Department of Chemistry, The University of Texas at Austin, Austin, TX, USA.
Meredith L Spradlin *Department of Chemistry, The University of Texas at Austin, Austin, TX, USA.
Michael KeatingDepartment of Chemistry, The University of Texas at Austin, Austin, TX, USA.
Igor PereiraDepartment of Chemistry, The University of Texas at Austin, Austin, TX, USA.
Elaine SturDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emine BayraktarDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Katherine I FosterDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7714-246X
Nicholas W BatemanGynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4425-9511
Waleed BarakatGynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Kathleen M DarcyGynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2888-2968
Thomas P ConradsGynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-4742-3281
G Larry MaxwellGynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Philip L LorenziDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-0385-7774
Susan K LutgendorfDepartments of Psychological and Brain Sciences, Obstetrics and Gynecology, and Urology, University of Iowa, Iowa City, IA, USA.
Yunfei WenDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li ZhaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Premal H ThakerDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University, St. Louis, MO, USA.
Michael J GoodheartDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Iowa, Iowa City, IA, USA.
Jinsong LiuDepartment of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nicole FlemingDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sanghoon LeeDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Livia S EberlinDepartment of Surgery, Baylor College of Medicine, Houston, TX, USA. Livia.Eberlin@bcm.edu.
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. asood@mdanderson.org.ORCID http://orcid.org/0000-0003-4242-1762
The University of Texas MD Anderson Cancer Center · USThe University of Texas at Austin · USHenry M. Jackson Foundation · USInova Health System · USUniversity of Iowa · USBaylor College of Medicine · USWashington University in St. Louis · US

Funding

U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C, SOOD, ANIL K · 2017 to 2021
$7.9M
Harnessing the power of exosomes for non-coding RNA deliveryR35CA209904 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2023
$5.0M
Behavioral Influences on Ovarian Cancer Progression: Role of ChemoresistanceR01CA193249 · NCI · UNIVERSITY OF IOWA · PI LUTGENDORF, SUSAN K · 2016 to 2020
$3.2M
NCI NIH HHS P50 CA217685NCI NIH HHS R01 CA193249NCI NIH HHS R35 CA209904
6 · The paper itself

Abstract

In this study, we investigated the metabolic alterations associated with clinical response to chemotherapy in patients with ovarian cancer. Pre- and post-neoadjuvant chemotherapy (NACT) tissues from patients with high-grade serous ovarian cancer (HGSC) who had poor response (PR) or excellent response (ER) to NACT were examined. Desorption electrospray ionization mass spectrometry (DESI-MS) was performed on sections of HGSC tissues collected according to a rigorous laparoscopic triage algorithm. Quantitative MS-based proteomics and phosphoproteomics were performed on a subgroup of pre-NACT samples. Highly abundant metabolites in the pre-NACT PR tumors were related to pyrimidine metabolism in the epithelial regions and oxygen-dependent proline hydroxylation of hypoxia-inducible factor alpha in the stromal regions. Metabolites more abundant in the epithelial regions of post-NACT PR tumors were involved in the metabolism of nucleotides, and metabolites more abundant in the stromal regions of post-NACT PR tumors were related to aspartate and asparagine metabolism, phenylalanine and tyrosine metabolism, nucleotide biosynthesis, and the urea cycle. A predictive model built on ions with differential abundances allowed the classification of patients' tumor responses as ER or PR with 75% accuracy (10-fold cross-validation ridge regression model). These findings offer new insights related to differential responses to chemotherapy and could lead to novel actionable targets.

Identifiers

PMID37923835
PMCPMC10624842
OpenAlexW4388303495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.